These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35673960)

  • 1. Retrospective study on the safety of COVID-19 vaccination in myasthenia gravis.
    Urra Pincheira A; Alnajjar S; Katzberg H; Barnett C; Daniyal L; Rohan R; Bril V
    Muscle Nerve; 2022 Nov; 66(5):558-561. PubMed ID: 35673960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telephone consultation for myasthenia gravis care during the COVID-19 pandemic: Assessment of a novel virtual myasthenia gravis index.
    Menon D; Alnajjar S; Barnett C; Vijayan J; Katzberg H; Fathi D; Alcantara M; Bril V
    Muscle Nerve; 2021 Jun; 63(6):831-836. PubMed ID: 33792967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of mRNA COVID-19 vaccines in patients with well-controlled myasthenia gravis.
    Gamez J; Gamez A; Carmona F
    Muscle Nerve; 2022 Nov; 66(5):612-617. PubMed ID: 36029224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An observational study on the safety of COVID-19 vaccination in patients with myasthenia gravis.
    Wang HY; Qiu L; Ou CY; Lin ZQ; Huang ZD; Chen P; Ma Q; Lu YR; Ran H; Liu WB
    Neurol Sci; 2023 Jul; 44(7):2239-2245. PubMed ID: 37160544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of SARS-CoV-2 immunization on COVID-19 disease course in people with myasthenia gravis.
    Bakirtzis C; Boziki MK; Karakasi MV; Moysiadis T; Grigoriadis N
    Muscle Nerve; 2023 May; 67(5):412-416. PubMed ID: 36814101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features and outcomes of Myasthenia Gravis associated with COVID-19 vaccines: A systematic review and pooled analysis.
    Tayebi AH; Samimisedeh P; Jafari Afshar E; Ayati A; Ghalehnovi E; Foroutani L; Abbasi Khoshsirat N; Rastad H
    Medicine (Baltimore); 2023 Oct; 102(40):e34890. PubMed ID: 37800781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review.
    Peng S; Tian Y; Meng L; Fang R; Chang W; Yang Y; Li S; Shen Q; Ni J; Zhu W
    Front Immunol; 2022; 13():1103020. PubMed ID: 36618419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience.
    Farina A; Falso S; Cornacchini S; Spagni G; Monte G; Mariottini A; Massacesi L; Barilaro A; Evoli A; Damato V
    Eur J Neurol; 2022 Aug; 29(8):2505-2510. PubMed ID: 35390184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the single simple question and the patient acceptable symptom state in myasthenia gravis.
    Menon D; Barnett C; Bril V
    Eur J Neurol; 2020 Nov; 27(11):2286-2291. PubMed ID: 32537828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of COVID-19 Infection and Vaccination Among Individuals With Myasthenia Gravis.
    Alcantara M; Koh M; Park AL; Bril V; Barnett C
    JAMA Netw Open; 2023 Apr; 6(4):e239834. PubMed ID: 37097637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study.
    Ruan Z; Huan X; Su Y; Tang YL; Meng DD; Ren DL; Li CH; Hao SJ; Zhao CB; Luo SS; Li ZY; Chang T
    Front Immunol; 2023; 14():1141983. PubMed ID: 37223097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study.
    Li HY; Shao LY; Song M; Hu SM; Yue YX; Li HF
    Front Immunol; 2022; 13():923017. PubMed ID: 35990671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis.
    Lotan I; Hellmann MA; Friedman Y; Stiebel-Kalish H; Steiner I; Wilf-Yarkoni A
    Neuromuscul Disord; 2022 Mar; 32(3):230-235. PubMed ID: 35227552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis.
    Zhou Q; Zhou R; Yang H; Yang H
    Front Immunol; 2021; 12():733418. PubMed ID: 34603311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between COVID-19 vaccination and myasthenia gravis: A population-based, nested case-control study.
    Arbel A; Bishara H; Barnett-Griness O; Cohen S; Najjar-Debbiny R; Gronich N; Auriel E; Saliba W
    Eur J Neurol; 2023 Dec; 30(12):3868-3876. PubMed ID: 37552795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients.
    Sansone G; Bonifati DM
    J Neurol; 2022 Aug; 269(8):3965-3981. PubMed ID: 35503373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 infection and vaccination against SARS-CoV-2 in myasthenia gravis.
    Peric S; Rankovic M; Bozovic I; Radosavljevic V; Marjanovic I; Basta I; Lavrnic D
    Acta Neurol Belg; 2023 Apr; 123(2):529-536. PubMed ID: 36279094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis.
    Vijayan J; Menon D; Barnett C; Katzberg H; Lovblom LE; Bril V
    Muscle Nerve; 2021 Oct; 64(4):462-466. PubMed ID: 34235762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New-onset myasthenia gravis after mRNA SARS-CoV-2 vaccination: a case series.
    Fanella G; Baiata C; Candeloro E; Toscano G; Colnaghi S; Mauri M; Cariddi LP; Rebecchi V; Solazzo F; Banfi P; Piatti M; Ferrarese C; Versino M
    Neurol Sci; 2022 Oct; 43(10):5799-5802. PubMed ID: 35870026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.